<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0CF6353C-24C9-4866-99CF-FB1DB633AF6F"><gtr:id>0CF6353C-24C9-4866-99CF-FB1DB633AF6F</gtr:id><gtr:name>University of North Carolina at Chapel Hill</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4AC4427C-1C27-4665-9256-F5448806A637"><gtr:id>4AC4427C-1C27-4665-9256-F5448806A637</gtr:id><gtr:name>Maastricht University (UM)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:department>School of Medicine</gtr:department><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0CF6353C-24C9-4866-99CF-FB1DB633AF6F"><gtr:id>0CF6353C-24C9-4866-99CF-FB1DB633AF6F</gtr:id><gtr:name>University of North Carolina at Chapel Hill</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4AC4427C-1C27-4665-9256-F5448806A637"><gtr:id>4AC4427C-1C27-4665-9256-F5448806A637</gtr:id><gtr:name>Maastricht University (UM)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6AF2161E-C2A6-4509-9BCC-400900D1A17D"><gtr:id>6AF2161E-C2A6-4509-9BCC-400900D1A17D</gtr:id><gtr:firstName>Helen</gtr:firstName><gtr:surname>Philippou</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3BDEBDD1-9F4A-4C59-AB40-AD5048D9E1C1"><gtr:id>3BDEBDD1-9F4A-4C59-AB40-AD5048D9E1C1</gtr:id><gtr:firstName>V</gtr:firstName><gtr:surname>Ridger</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FA7AD4BD-2422-4924-AA98-5C587F388CDE"><gtr:id>FA7AD4BD-2422-4924-AA98-5C587F388CDE</gtr:id><gtr:firstName>Robert</gtr:firstName><gtr:surname>Ariens</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0901546"><gtr:id>761BDFE4-CCBF-43E5-98B4-B39AB58630A2</gtr:id><gtr:title>Role of coagulation factor XIII in fibrin clot structure and thrombosis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0901546</gtr:grantReference><gtr:abstractText>Clot formation within a blood vessel is the predominant cause of heart attacks, stroke and deep vein thrombosis. The clot is composed of a protein called fibrin which undergoes cross-linking by an enzyme called transglutaminase (factor XIII). The role of factor XIII in clot structure and thrombosis is not well understood. Our research is aimed at discovering how the thrombus is modulated by factor XIII, using model systems of clot formation, engineered proteins and in vivo models. This study will develop better understanding of processes involved in clot stability and in the future will help to design new anti-clotting drugs.</gtr:abstractText><gtr:technicalSummary>The thrombus is composed of a mesh of fibrin fibres, with platelets, erythrocytes and other cells embedded in this network. The clot is stabilised by cross-linking activity of transglutaminase FXIIIa. The effect(s) of cross-linking on fibrin clot structure and on risk for thrombosis are unknown. The aims of this project are to characterise 1) effects of cross-linking on fibrin structure and mechanisms by which effects occurs, 2) the relationship between fibrin cross-linking and FXIII activation, and 3) the contribution of cross-linking to in vivo thrombus formation. Understanding the mechanisms that regulate clot stability will facilitate discovery of new treatments for thrombosis.</gtr:technicalSummary><gtr:fund><gtr:end>2013-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>330620</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of North Carolina at Chapel Hill</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Pathology and Laboratory Medicine</gtr:department><gtr:description>Alisa Wolberg</gtr:description><gtr:id>EA4D80AC-DD1D-4E6D-B4AF-7E79308AAB35</gtr:id><gtr:impact>Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin a-chain crosslinking.
Byrnes JR, Duval C, Wang Y, Hansen CE, Ahn B, Mooberry MJ, Clark MA, Johnsen JM, Lord ST, Lam WA, Meijers JC, Ni H, Ari&amp;euml;ns RA, Wolberg AS.
Blood. 2015 Oct 15;126(16):1940-8.</gtr:impact><gtr:outcomeId>56de9d933505f9.15977826-1</gtr:outcomeId><gtr:partnerContribution>We collaborate with the Wolberg lab by exchange of proteins and cells, which leads to joint publications in high-impact journals.</gtr:partnerContribution><gtr:piContribution>Dr Cedric Duval and I contributed invaluable proteins and cells for the research, assisted in research design and interpreted data.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Maastricht University (UM)</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Elisabetta Castoldi</gtr:description><gtr:id>93EE1B58-05EF-4A84-B081-A766506CD3FE</gtr:id><gtr:impact>Fibrinogen ?' increases the sensitivity to activated protein C in normal and factor V Leiden plasma.
Omarova F, Uitte de Willige S, Simioni P, Ari&amp;euml;ns RA, Bertina RM, Rosing J, Castoldi E.
Blood. 2014 Aug 28;124(9):1531-8. doi: 10.1182/blood-2014-02-554055. Epub 2014 Jun 20.
 
Inhibition of thrombin-mediated factor V activation contributes to the anticoagulant activity of fibrinogen ?'.
Omarova F, Uitte De Willige S, Ari&amp;euml;ns RA, Rosing J, Bertina RM, Castoldi E.
J Thromb Haemost. 2013 Sep;11(9):1669-78. doi: 10.1111/jth.12354.</gtr:impact><gtr:outcomeId>56de9f6a89c170.56206536-1</gtr:outcomeId><gtr:partnerContribution>Development of new research techniques and new research area.</gtr:partnerContribution><gtr:piContribution>My laboratory has provided invaluable research reagents (protein), assisted in study design, obtained joint grant income, and interpreted data.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Maastricht University (UM)</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Hugo ten Cate</gtr:description><gtr:id>8BBBC9FC-7403-4A33-B50D-588C7C50BA81</gtr:id><gtr:impact>Clot structure and fibrinolytic potential in patients with post thrombotic syndrome.
Bouman AC, McPherson H, Cheung YW, Ten Wolde M, Ten Cate H, Ari&amp;euml;ns RA, Ten Cate-Hoek AJ.
Thromb Res. 2016 Jan;137:85-91. doi: 10.1016/j.thromres.2015.11.013. Epub 2015 Nov 10.

The role of activated coagulation factor XII in overall clot stability and fibrinolysis.
Konings J, Hoving LR, Ari&amp;euml;ns RS, Hethershaw EL, Ninivaggi M, Hardy LJ, de Laat B, Ten Cate H, Philippou H, Govers-Riemslag JW.
Thromb Res. 2015 Aug;136(2):474-80. doi: 10.1016/j.thromres.2015.06.028. Epub 2015 Jun 19.

Factor XIIa regulates the structure of the fibrin clot independently of thrombin generation through direct interaction with fibrin.
Konings J, Govers-Riemslag JW, Philippou H, Mutch NJ, Borissoff JI, Allan P, Mohan S, Tans G, Ten Cate H, Ari&amp;euml;ns RA.
Blood. 2011 Oct 6;118(14):3942-51. doi: 10.1182/blood-2011-03-339572.</gtr:impact><gtr:outcomeId>56dea051ddce77.44103707-1</gtr:outcomeId><gtr:partnerContribution>The ten Cate laboratory and my laboratory exchange samples, reagents and researchers for several collaborative studies.</gtr:partnerContribution><gtr:piContribution>The ten Cate laboratory and my laboratory exchange samples, reagents and researchers for several collaborative studies.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>On Blood Clotting and Thrombosis: The Clot Thickens</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FC38D803-469E-4306-BD38-4177BE17A558</gtr:id><gtr:impact>Increased awareness of research group's activity

Invited to speak at other occasions</gtr:impact><gtr:outcomeId>546491d27e0f59.33628501</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ISTH 2013 State-of-the-Art Lecture on the Role of Fibrin(ogen) in Thrombostic Disease</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>39B33183-3A14-4AF1-A960-BA964187C1F4</gtr:id><gtr:impact>The PI was invited to give a lecture on Fibrin(ogen) and Thrombotic Disease at the 2013 ISTH Congress in Amsterdam, June 29 - July 4

This was a state-of-the-art lecture at the main international conference on Thrombosis and Haemostasis (ISTH) by the PI. Ariens also wrote a manuscript and there were a few of oral communication sessions on the topic at the meeting.</gtr:impact><gtr:outcomeId>MsJAuHVD8Rn</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>FASEB 2013 Regulation of fibrin structure and its role in thrombosis</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C9DC2BDA-25CB-4708-BA7F-4456C62105DE</gtr:id><gtr:impact>This was an invited presentation at the 2013 FASEB meeting on proteases in haemostasis by Ariens.

The meeting allowed exposure of our most recent studies to international peer colleagues and USA colleagues in particular.</gtr:impact><gtr:outcomeId>M8A4MncLKTf</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>https://secure.faseb.org/FASEB/meetings/summrconf/Programs/11531.pdf</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press release and publication</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>4A1C43EA-687F-4080-B7D8-4D5E8FFF4ECE</gtr:id><gtr:impact>Our new BHF research programme award featured in the Yorkshire Post and Yorkshire Evening Post, July 2013. 


Raising local public awareness of our research on clot structure.</gtr:impact><gtr:outcomeId>ChdtmsFpt3X</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Sky television interview</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>92B37DF3-51C7-4E26-A5E5-4ACCC7E4276C</gtr:id><gtr:impact>The PI (Ariens) discussed thrombosis on live Sky Television (Chrissy B show, August 2013)

Raising awareness of thrombosis and clotting with the general public</gtr:impact><gtr:outcomeId>HYHane6JPpo</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.youtube.com/watch?v=Y68kntUqkZY</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1145224</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Programme Grant</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:fundingRef>RG/13/3/30104</gtr:fundingRef><gtr:id>85C6FF16-7BE4-44C4-90BD-BCC3ADD9CB57</gtr:id><gtr:outcomeId>58c2a5cf860682.81696512</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Genome Editing Mice For Medicine (GEMM) Initiative</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Research Complex at Harwell</gtr:fundingOrg><gtr:id>861E4412-1E08-41C9-9E60-996118E10246</gtr:id><gtr:outcomeId>58ca8a4dce36a9.08670969</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Official ISTH SSC publication on FXIII deficiency</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>93A5008B-2EF6-403C-ABB8-3DCFDB49BBB0</gtr:id><gtr:outcomeId>d1EbLucznTQ</gtr:outcomeId><gtr:type>Implementation circular/rapid advice/letter to e.g. Ministry of Health</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Official ISTH SSC publication on standard clot permeation method</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>2C35EE1C-9CB5-4E1D-82B0-B72C81B22590</gtr:id><gtr:outcomeId>j4SanbfMboE</gtr:outcomeId><gtr:type>Implementation circular/rapid advice/letter to e.g. Ministry of Health</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Magnetic tweezers have been developed in our laboratory to study the visco-elastic properties of the fibrin clot.</gtr:description><gtr:id>998DD494-A933-4550-8635-639BA02F459E</gtr:id><gtr:impact>We are the only laboratory currently using this methodology for fibrin clots worldwide.</gtr:impact><gtr:outcomeId>Uh4A1hMGB2K</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Magnetic Tweezers</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We study structural and kynetic processes involved fibrin polymerisation at sub-molecular level using atomic force microscopy (AFM).</gtr:description><gtr:id>7874BF19-25B6-435A-841E-5A2AC09D9D8E</gtr:id><gtr:impact>We are currently the only laboratory in the world studying fibrin polymerisation at high molecular resolution using the AFM. We have interest from several peers (Aberdeen and Geneva) who wish to collaborate and learn this methodology.</gtr:impact><gtr:outcomeId>s2egUR52dVL</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>AFM study of fibrin polymerisation</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We express recombinant human fibrinogen and variants thereof in CHO and BHK cells.</gtr:description><gtr:id>1BB75F73-5072-4FA8-BE74-027615302F4E</gtr:id><gtr:impact>We are one of a few laboratories around the world currently expressing recombinant human fibrinogen.</gtr:impact><gtr:outcomeId>cCPeDFw5HuE</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Recombinant fibrinogen expression</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have developed a murine FeCl3 and laser induced thrombosis model of thrombosis in the femoral vessels and cremaster arterioles. We also have factor XIII deficient and fibinogen deficient mice available for studies with recombinant FXIII and fibrinogen variants.</gtr:description><gtr:id>C2B79AC3-456F-4F94-B834-F6B13989E6C4</gtr:id><gtr:impact>Our in vivo thrombosis model is unique in that we have developed excvellent quntification tools for kinetic analysis of thrombus growth, size and fibrinolysis rates.</gtr:impact><gtr:outcomeId>Tc3XnbkNt7y</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>In vivo thrombosis model</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We express recombinant human blood coagulation factor XIII and variants thereof in E Coli.</gtr:description><gtr:id>ED52258D-7237-41B5-9EA6-3F2E4FA6439B</gtr:id><gtr:impact>We are one of a few laboratories around the world currently expression recombinant human FXIII</gtr:impact><gtr:outcomeId>tgpPrkHkiKX</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Recombinant FXIII expression</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>As part of the methods devloped for this grant, we have developed a powerful new method of Laser scanning confocal imaging of fibrin polymerisation.</gtr:description><gtr:id>FD9248F5-E565-49F8-95DF-7D189013F940</gtr:id><gtr:impact>The new method of Laser scanning confocal imaging of fibrin polymerisation enables us to integrate fibrin polymerisation data from light scattering with morphological analysis of fibrin formation.</gtr:impact><gtr:outcomeId>KhBByQbPnfr</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Laser scanning confocal imaging of fibrin polymerisation</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>C5991483-EE90-40F0-BF0A-CAD34B1E84EF</gtr:id><gtr:title>Role of fibrin structure in thrombosis and vascular disease.</gtr:title><gtr:parentPublicationTitle>Advances in protein chemistry and structural biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/777b5fa3e565a3bd0062a0e1764bf90e"><gtr:id>777b5fa3e565a3bd0062a0e1764bf90e</gtr:id><gtr:otherNames>Cilia La Corte AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1876-1623</gtr:issn><gtr:outcomeId>54648d78d14880.14040134</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>447E21D5-F2E0-49D8-8C74-501431FED36E</gtr:id><gtr:title>Clot properties and cardiovascular disease.</gtr:title><gtr:parentPublicationTitle>Thrombosis and haemostasis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45b3fcb80bab4db1ea97e5a9be598953"><gtr:id>45b3fcb80bab4db1ea97e5a9be598953</gtr:id><gtr:otherNames>Bridge KI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0340-6245</gtr:issn><gtr:outcomeId>54648d7b3cffc3.49330038</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1AE2665-77D7-46A3-A86C-319C04E2C49A</gtr:id><gtr:title>Partial deletion of the aC-domain in the Fibrinogen Perth variant is associated with thrombosis, increased clot strength and delayed fibrinolysis.</gtr:title><gtr:parentPublicationTitle>Thrombosis and haemostasis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/69882978360f01969a69f359e9dff0d8"><gtr:id>69882978360f01969a69f359e9dff0d8</gtr:id><gtr:otherNames>Westbury SK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0340-6245</gtr:issn><gtr:outcomeId>pm_13276_26_24048413</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DCE3768F-1FE9-43B6-ABAC-C3EB57D9ECBD</gtr:id><gtr:title>Roles of fibrin a- and ?-chain specific cross-linking by FXIIIa in fibrin structure and function.</gtr:title><gtr:parentPublicationTitle>Thrombosis and haemostasis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1297f69f265831ecfc050b9960501209"><gtr:id>1297f69f265831ecfc050b9960501209</gtr:id><gtr:otherNames>Duval C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0340-6245</gtr:issn><gtr:outcomeId>pm_540e16ee16e2eb7d6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>120EDD90-23DB-4632-8B2C-807708C5E0CA</gtr:id><gtr:title>Evidence that fibrinogen ?' directly interferes with protofibril growth: implications for fibrin structure and clot stiffness.</gtr:title><gtr:parentPublicationTitle>Journal of thrombosis and haemostasis : JTH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a2e380e0109960cd8169e2b3ade981fb"><gtr:id>a2e380e0109960cd8169e2b3ade981fb</gtr:id><gtr:otherNames>Allan P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1538-7836</gtr:issn><gtr:outcomeId>pm_13276_26_22463367</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13BDEC72-5B7D-4A9B-B150-44D98A5F3243</gtr:id><gtr:title>Clot architecture is altered in abdominal aortic aneurysms and correlates with aneurysm size.</gtr:title><gtr:parentPublicationTitle>Arteriosclerosis, thrombosis, and vascular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b462546b5b4a9e08fbdce064602275d"><gtr:id>3b462546b5b4a9e08fbdce064602275d</gtr:id><gtr:otherNames>Scott DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1079-5642</gtr:issn><gtr:outcomeId>54648d793d4be8.92588609</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>59E7DED0-3BBE-402C-A7F6-8E5251D5EC7A</gtr:id><gtr:title>Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases.</gtr:title><gtr:parentPublicationTitle>Arteriosclerosis, thrombosis, and vascular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/945912ab78778bd0c2d1f43959e7fa20"><gtr:id>945912ab78778bd0c2d1f43959e7fa20</gtr:id><gtr:otherNames>Undas A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1079-5642</gtr:issn><gtr:outcomeId>pm_13276_26_21836064</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1AE138EB-48E6-4FC2-AD0F-DF7785666FE8</gtr:id><gtr:title>Factor XIII A-Subunit V34L Variant Affects Thrombus Cross-Linking in a Murine Model of Thrombosis.</gtr:title><gtr:parentPublicationTitle>Arteriosclerosis, thrombosis, and vascular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1297f69f265831ecfc050b9960501209"><gtr:id>1297f69f265831ecfc050b9960501209</gtr:id><gtr:otherNames>Duval C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1079-5642</gtr:issn><gtr:outcomeId>56de994df2a321.86517672</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC356C36-45E7-4A51-AE80-99F83AF0240D</gtr:id><gtr:title>The effect of blood coagulation factor XIII on fibrin clot structure and fibrinolysis.</gtr:title><gtr:parentPublicationTitle>Journal of thrombosis and haemostasis : JTH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0155b719f19a1f7fb15b146c44b458d9"><gtr:id>0155b719f19a1f7fb15b146c44b458d9</gtr:id><gtr:otherNames>Hethershaw EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1538-7836</gtr:issn><gtr:outcomeId>XEEqMw6uSLs</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A33F3164-72A0-4AAB-91F0-85FE061587F9</gtr:id><gtr:title>An international study on the standardization of fibrin clot permeability measurement: methodological considerations and implications for healthy control values.</gtr:title><gtr:parentPublicationTitle>Journal of thrombosis and haemostasis : JTH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a320d40658506be709f2957b03fb827"><gtr:id>7a320d40658506be709f2957b03fb827</gtr:id><gtr:otherNames>Pieters M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1538-7836</gtr:issn><gtr:outcomeId>54648d79923538.01473548</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>931F769E-5CB4-43AA-951B-2BAADE8EF97C</gtr:id><gtr:title>Fibrinogen splice variation and cross-linking: Effects on fibrin structure/function and role of fibrinogen ?' as thrombomobulin II.</gtr:title><gtr:parentPublicationTitle>Matrix biology : journal of the International Society for Matrix Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1297f69f265831ecfc050b9960501209"><gtr:id>1297f69f265831ecfc050b9960501209</gtr:id><gtr:otherNames>Duval C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0945-053X</gtr:issn><gtr:outcomeId>58c292a6cfc9d7.90598012</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F0901597-6996-482C-A386-F7915A4B08BB</gtr:id><gtr:title>Dysfibrinogenemia: from molecular anomalies to clinical manifestations and management.</gtr:title><gtr:parentPublicationTitle>Journal of thrombosis and haemostasis : JTH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/705485c811ca0a5575a71429e9edaefc"><gtr:id>705485c811ca0a5575a71429e9edaefc</gtr:id><gtr:otherNames>Casini A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1538-7836</gtr:issn><gtr:outcomeId>56de994f85d645.60858500</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6AFDD11B-BF3F-4376-A013-92888463095D</gtr:id><gtr:title>Ranking reactive glutamines in the fibrinogen aC region that are targeted by blood coagulant factor XIII.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17f0bb23cbb17e823e2b368509653ec2"><gtr:id>17f0bb23cbb17e823e2b368509653ec2</gtr:id><gtr:otherNames>Mouapi KN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>58c292a81c0fc3.47560060</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E06A7706-ECB0-415E-9BCD-8C5071FB4EEE</gtr:id><gtr:title>Thrombin and fibrinogen ?' impact clot structure by marked effects on intrafibrillar structure and protofibril packing.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0a5fe8fd60654a44cf10a6c0faeee877"><gtr:id>0a5fe8fd60654a44cf10a6c0faeee877</gtr:id><gtr:otherNames>Domingues MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>56de994e256cd4.05133494</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>748F1D64-F9F6-4A50-B891-94795836E79B</gtr:id><gtr:title>Evidence that fibrinogen ?' regulates plasma clot structure and lysis and relationship to cardiovascular risk factors in black Africans.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a320d40658506be709f2957b03fb827"><gtr:id>7a320d40658506be709f2957b03fb827</gtr:id><gtr:otherNames>Pieters M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>54648d7a1ff710.48736656</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A52ACA6E-0952-4873-A3FE-CF3334B56514</gtr:id><gtr:title>Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin a-chain crosslinking.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3816ba649a712380881ca4d11fed310"><gtr:id>f3816ba649a712380881ca4d11fed310</gtr:id><gtr:otherNames>Byrnes JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>56de994f2b1a05.89267070</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B438668-312E-4F99-A467-5E22F01B20D8</gtr:id><gtr:title>Factor XIIa regulates the structure of the fibrin clot independently of thrombin generation through direct interaction with fibrin.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/930968068f4e7eee67a47052b4bd2e59"><gtr:id>930968068f4e7eee67a47052b4bd2e59</gtr:id><gtr:otherNames>Konings J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_13276_26_21828145</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C6C3172-D7DE-4347-982A-1AAF20E7E47D</gtr:id><gtr:title>Counting 1 fibrin molecule at a time.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b050118278446a168e9c1dba140a8188"><gtr:id>b050118278446a168e9c1dba140a8188</gtr:id><gtr:otherNames>Ari?ns RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>54648d7a472221.93886589</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9202B3EC-4557-41AF-88D9-92A20B59000F</gtr:id><gtr:title>Fibrin(ogen) and thrombotic disease.</gtr:title><gtr:parentPublicationTitle>Journal of thrombosis and haemostasis : JTH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b050118278446a168e9c1dba140a8188"><gtr:id>b050118278446a168e9c1dba140a8188</gtr:id><gtr:otherNames>Ari?ns RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1538-7836</gtr:issn><gtr:outcomeId>pm_13276_26_23809133</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BBCE9743-C752-42F2-BE42-25E862D147E5</gtr:id><gtr:title>a-a Cross-links increase fibrin fiber elasticity and stiffness.</gtr:title><gtr:parentPublicationTitle>Biophysical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/06284be44992d175931991e923415f65"><gtr:id>06284be44992d175931991e923415f65</gtr:id><gtr:otherNames>Helms CC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-3495</gtr:issn><gtr:outcomeId>pm_13276_26_22225811</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C48C6E4-1B2D-4D6A-9EB1-EFA006CE002B</gtr:id><gtr:title>The activation peptide cleft exposed by thrombin cleavage of FXIII-A(2) contains a recognition site for the fibrinogen a chain.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/581c2323d81abc2c1a933f74383df840"><gtr:id>581c2323d81abc2c1a933f74383df840</gtr:id><gtr:otherNames>Smith KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>54648d79baf606.65080477</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>21A2EFF6-FA99-487C-95DD-3012E8DA2814</gtr:id><gtr:title>Interactions between factor XIII and the alphaC region of fibrinogen.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/581c2323d81abc2c1a933f74383df840"><gtr:id>581c2323d81abc2c1a933f74383df840</gtr:id><gtr:otherNames>Smith KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>54648d7854d254.72131912</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E3A19E8-1E0B-4650-8B09-1F50F7DEC494</gtr:id><gtr:title>Elevated fibrinogen causes thrombosis.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b050118278446a168e9c1dba140a8188"><gtr:id>b050118278446a168e9c1dba140a8188</gtr:id><gtr:otherNames>Ari?ns RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>54648d78aa6536.64476403</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>07F94863-E52B-4BB5-BB09-E01DB838951F</gtr:id><gtr:title>Proteolytic and genetic variation of the alpha-2-antiplasmin C-terminus in myocardial infarction.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e0340bed9b677ed35f60b25e3ec7c9a"><gtr:id>0e0340bed9b677ed35f60b25e3ec7c9a</gtr:id><gtr:otherNames>Uitte de Willige S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>54648d787b5e72.43904768</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>83C15665-D302-48F5-89FE-040F344A6013</gtr:id><gtr:title>Relationship of coagulation and fibrinolytic variables with arterial structure and function in Africans.</gtr:title><gtr:parentPublicationTitle>Thrombosis research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a320d40658506be709f2957b03fb827"><gtr:id>7a320d40658506be709f2957b03fb827</gtr:id><gtr:otherNames>Pieters M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0049-3848</gtr:issn><gtr:outcomeId>pm_540e16ee16e391d30</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E99A9E09-5762-41BE-94BF-2F2E2FF458EC</gtr:id><gtr:title>Gender-specific alterations in fibrin structure function in type 2 diabetes: associations with cardiometabolic and vascular markers.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45966772f9f56b02fed5080346c3b8b6"><gtr:id>45966772f9f56b02fed5080346c3b8b6</gtr:id><gtr:otherNames>Alzahrani SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>54648d796bd114.28202818</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>95A8B4B0-CCC4-40A8-82A8-F331BBD523EB</gtr:id><gtr:title>Elimination of coagulation factor&amp;nbsp;XIII from fibrinogen preparations.</gtr:title><gtr:parentPublicationTitle>Journal of thrombosis and haemostasis : JTH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4bea07cbd993ceb52de57e820d91998"><gtr:id>a4bea07cbd993ceb52de57e820d91998</gtr:id><gtr:otherNames>Smith EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1538-7836</gtr:issn><gtr:outcomeId>54648d79ec0a39.51766977</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08EF253F-52C3-41DF-B641-25D515898947</gtr:id><gtr:title>Diagnosis and classification of factor XIII deficiencies.</gtr:title><gtr:parentPublicationTitle>Journal of thrombosis and haemostasis : JTH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df6815c178a9fe11ff95439acfed6338"><gtr:id>df6815c178a9fe11ff95439acfed6338</gtr:id><gtr:otherNames>Kohler HP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1538-7836</gtr:issn><gtr:outcomeId>54648d790f4c66.83990503</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0901546</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>939798CA-B6AE-4C12-9DCC-A0F88F84E6F3</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Blood</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>